Skip to main content
Signal8

PMGC Holdings Inc. (ELAB)

PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

PMGC Holdings Inc. logo

PMGC Holdings Inc.

NASDAQ:ELABHealthcare
AH+1.35%$1.50
Close$1.48-10.84%
Mkt Cap$1.73M
EV-
Float1.17M
O/S1.17M
VOL159K sh
$ Vol$248K
RVOL0.22×
Inst Own1.7%
SI1.6%
Net Cash/Sh-
Dilution
PMGC Holdings Inc. logoNASDAQ:ELABAH$1.50+1.35%

PMGC Holdings Inc. (ELAB) dilution facts from SEC filings

Snapshot as of Sep 30, 2026, built from 34 SEC filings.

Shelf registration
S-3 filed Jan 27, 2025, effective Feb 7, 2025
Source: 424B5 filed Apr 20, 2026
At-the-market (ATM) program
Yes
Source: 10-Q filed Nov 13, 2026
Warrants outstanding
5 warrant series recorded as outstanding
Most recent offering
Offering, closed Apr 20, 2026
Source: 424B5 filed Apr 20, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro